Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Recruiting now · Not applicable

Conditions studied: ALK+ Non-Small-Cell Lung Carcinoma

In brief

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context

Key facts

Study ID: NCT06487078
Run by: Pfizer
People needed: 90
Starts: 2025-01-20
Expected to finish: 2028-11-30
Last updated by the study team: 2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

CHBA — Vannes, France (enrolling)
Centre Hospitalier du Pays d AIX — Aix-en-Provence, France (enrolling)
CH ALBI — Albi, France (enrolling)
Chu Amiens Sud — Amiens, France (enrolling)
Ch Cornouaille — Quimper, France (enrolling)
Institut Godinot — Reims, France (enrolling)
Hopital Pontchaillou — Rennes, France (enrolling)
Hopital Foch — Suresnes, France (enrolling)
CHRU Bretonneau — Tours, France (enrolling)
Ch Troyes — Troyes, France (enrolling)
Hopital de Rangueil — TSA 50032 Toulouse, France (enrolling)
Clinique Teissier — Valenciennes, France (enrolling)
Institut Curie — Paris, Paris, France (enrolling)
CHIC — Créteil, France (enrolling)
Clcc Georges Francois Leclerc — Dijon, France (enrolling)
Chu Limoges — Limoges, France (enrolling)
Hopital Robert Schuman de Vantoux — Metz, France (enrolling)
CHU Nantes — Nantes, France (enrolling)
Hopital Saint Joseph — Paris, France (enrolling)
Hopital Europeen Georges Pompidou — Paris, France (enrolling)
Centre Hospitalier Francois Mitterand — Pau, France (enrolling)
Ch Annecy Genevois — Pringy, France (enrolling)
Ch Avignon — Avignon, France
Polyclinique Bordeaux Nord Aquitaine — Bordeaux, France
Institut Bergonie — Bordeaux, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.